-
D405-07-0500
Thomas Scientific
GUINEA PIG PLASMA (non-sterile) in Lithium Heparin, 500mL, Liquid
Price: $7,605.27List Price: $8,450.29pH: normal Immunoelectrophoresis: normal Hemoglobin: normal IgG Concentration: normal -
G275270-100mgStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
-
G275270-50mgStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
-
G3295-1MGBiochem/physiol Actions GW0742 is a highly selective PPARδ agonist. EC 50 = 1 nM vs 1 μM and 2 μM for PPARα and PPARγ, respectively.
-
G3295-5MGBiochem/physiol Actions GW0742 is a highly selective PPARδ agonist. EC 50 = 1 nM vs 1 μM and 2 μM for PPARα and PPARγ, respectively.
-
G5172-25MGGW4064 is a synthetic isoxazole, which is used to decipher the cellular and physiological functions of farnesoid X receptor (FXR). It is an estrogen receptor-related receptors (ERRs) agonist.
-
G5172-5MGGW4064 is a synthetic isoxazole, which is used to decipher the cellular and physiological functions of farnesoid X receptor (FXR). It is an estrogen receptor-related receptors (ERRs) agonist.
-
D1692-25MGGW4869 is a commonly used pharmacological agent, which inhibits exosome generation. It blocks ceramide-mediated inward budding of multivesicular bodies (MVBs) and the release of mature exosomes from MVBs.
-
D1692-5MGGW4869 is a commonly used pharmacological agent, which inhibits exosome generation. It blocks ceramide-mediated inward budding of multivesicular bodies (MVBs) and the release of mature exosomes from MVBs.
-
G6416-25MGApplication GW5074 has been used as a specific inhibitor of cRaf1 in C2 murine skeletal myoblasts, HT-29 colorectal adenocarcinoma cell line and neutrophils. Biochem/physiol Actions GW5074 is a cRaf1 kinase inhibitor, which is placed immediately
-
G6416-5MGApplication GW5074 has been used as a specific inhibitor of cRaf1 in C2 murine skeletal myoblasts, HT-29 colorectal adenocarcinoma cell line and neutrophils. Biochem/physiol Actions GW5074 is a cRaf1 kinase inhibitor, which is placed immediately
-
G5045-5MGGW6471 prevents apoptosis and cell cycle arrest at G 0 /G 1 in renal cell carcinoma. It reduces enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition.